Sector: HealthcareIndustry: Drug manufacturers - general

Abbvie Inc

NYSE: ABBV•https://www.abbvie.com

Current Price

Analyst Sentiment

28 ratings: Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

AbbVie Inc is a leading American biopharmaceutical company, established in 2013 from a spin-off of Abbott Laboratories. The company specializes in the research, development, and commercialization of advanced therapies in...|

Overview

Market Cap$396.55B

52W High / Low$243 / $160

P/E169.98

PEG0.41

Book Value$-1.50

Dividend/Share$6.56

Dividend Yield2.92%

EPS$1.32

Revenue/Share$33.72

OPM35.50%

NPM4.00%

ROA9.59%

ROE1.38%

Gross Profit$42.62B

Forward PE16.21

Price to Sales6.65

Price to Book50.46

EV to Sales7.80

EV to EBITDA36.38

Beta0.35

50D Moving Avg$227.59

200D Moving Avg$204.02

Institutional Holding75.12%

Insider Holding10.50%

Trailing P/E169.98

Qtr EPS Growth-88.70%

Qtr Revenue Growth9.10%

Add ratio to table

e.g. Promoter holding

Edit Ratios

Loading price data...

Earnings Estimates

Analyst consensus EPS and Revenue forecasts.

Show growth under values

Years:

Unit:

Metric (B)	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
EPS Estimate (avg)	$12.67	$13.76	$11.09	$10.39	$10.64	$14.24
Revenue Estimate (avg)	56.25	58.28	54.05	56.04	60.93	66.62
EPS Revision (30d avg)	+0.0%	-0.6%	-1.2%	-5.0%	+0.9%	+0.2%

Peer Comparison

Showing 5 peers (Same Industry)

S.No.	Name	Symbol	Market Cap	P/E	P/B	Profit Margin	Op. Margin	ROE	Rev. Growth
1.	Lilly(Eli) & Company	LLY	$937.80B	51.23	39.79	31.00%	48.30%	96.50%	53.90%
2.	Astrazeneca plc	AZN	$279.58B	30.06	6.12	16.20%	24.10%	21.70%	12.00%
3.	AMGEN Inc	AMGN	$182.20B	26.11	18.89	19.50%	34.20%	81.70%	12.40%
4.	Johnson & Johnson	JNJ	$494.92B	19.85	6.24	27.30%	30.20%	33.60%	6.80%
5.	Novartis AG	NVS	$253.82B	17.64	5.58	25.50%	31.90%	32.60%	9.00%

Quarterly Results

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Quarters:

Unit:

Quarter (M)	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25
Sales	14,301	12,310	14,462	14,460	15,102	13,343	15,423	15,776
Expenses	5,402	5,418	6,262	6,417	12,196	5,608	7,158	7,495
Operating Profit	1,776	2,415	2,872	2,804	-1,567	2,361	2,294	1,381
OPM %	12.42%	19.62%	19.86%	19.39%	-10.38%	17.69%	14.87%	8.75%
Other Income	0	0	0	0	0	0	0	0
Interest	-378	-453	-506	-591	-610	-627	-678	-595
Depreciation	2,076	2,074	2,131	2,079	2,102	2,039	2,050	2,063
Profit Before Tax	1,212	1,755	2,146	2,084	-2,269	1,661	1,554	714
Tax %	32.01%	21.82%	36.02%	24.95%	98.99%	22.4%	39.45%	73.67%
Net Profit	822	1,369	1,370	1,561	-22	1,286	944	186
EPS	0	0	0	0	0	0	0	0

Profit & Loss

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales	22,859	25,638	28,216	32,753	33,266	45,804	56,197	58,054	54,318	56,334
COGS	4,500	5,833	7,040	7,718	7,439	15,387	17,446	17,414	20,415	16,904
Gross Profit	18,359	19,805	21,176	25,035	25,827	30,417	38,751	40,640	33,903	39,430
Gross Profit %	80.31%	77.25%	75.05%	76.44%	77.64%	66.41%	68.96%	70%	62.42%	69.99%
Operating Exp	10,822	10,466	11,629	18,652	12,844	19,054	20,827	22,523	21,146	30,293
EBITDA	8,200	10,120	10,378	8,310	12,227	12,323	23,933	24,174	17,172	14,910
Other Income	-206	-535	-861	-42	-3,048	-5,685	-2,551	-2,596	0	0
Interest	160	-965	-1,004	-1,144	-1,509	-2,280	-2,384	-2,044	-1,684	-2,160
Depreciation	836	1,189	1,501	1,765	2,017	6,471	8,521	8,467	8,698	8,386
Profit Before Tax	6,645	7,884	7,727	5,197	8,426	3,398	12,989	13,477	6,250	3,716
Tax Rate %	22.59%	24.49%	31.29%	-9.43%	6.46%	-36.02%	11.09%	12.11%	22.03%	-15.34%
Net Profit	5,144	5,953	5,309	5,687	7,882	4,616	11,542	11,836	4,863	4,278

Balance Sheet

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash & Bank	8,399	5,100	9,303	7,289	39,924	8,449	9,746	9,201	12,814	5,524
Investments	153	3,106	2,576	2,192	93	323	361	269	306	310
Fixed Assets	2,565	2,604	2,803	2,883	2,962	5,248	5,110	4,935	0	0
Current Assets	7,907	9,764	11,434	8,884	9,595	15,694	18,098	19,234	20,186	20,027
Other Assets	34,026	45,525	44,670	38,104	36,541	120,851	113,214	105,166	101,405	109,300
Total Assets	53,050	66,099	70,786	59,352	89,115	150,565	146,529	138,805	134,711	135,161
Equity Capital	-8,822	-10,834	-11,905	-24,090	-24,486	-2,246	-3,125	-4,576	-6,515	18
Reserves	12,767	15,470	17,002	15,644	16,314	15,322	18,533	21,830	16,875	3,307
Borrowing/Debt	31,671	36,842	37,368	40,310	67,088	87,063	77,575	64,191	60,120	67,841
Current Liabilities	8,463	9,379	10,226	11,931	11,832	19,984	22,521	25,236	30,650	31,945
Other Liabilities	8,971	15,242	18,095	15,557	18,367	30,421	30,997	32,091	33,544	32,011
Total Liabilities & Equity	53,050	66,099	70,786	59,352	89,115	150,544	146,501	138,772	134,674	135,122

Cash Flow Statement

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash Flow from Operating	7,535	7,041	9,960	13,427	13,324	17,588	22,777	24,943	22,839	18,806
Cash Flow from Investing	-12,936	-6,074	-274	-1,006	596	-37,557	-2,344	-623	-2,009	-20,820
Cash Flow from Financing	5,752	-3,928	-5,512	-14,396	18,708	-11,501	-19,039	-24,803	-17,222	-5,211
Net Cash Flow	51	-3,299	4,203	-2,014	32,635	-31,475	1,297	-483	0	0